Clinicopathologic Implications of Eukaryotic Initiation Factor 3f and Her‐2/neu Expression in Gastric Cancer

Background: To detect the expression of eIF3f and human epidermal growth factor receptor 2 (Her‐2)/neu in gastric cancer (GC), correlation with their clinicopathological parameters and the relationship of eIF3f and Her‐2/neu in the occurrence and development of GC. Methods: A total of 195 gastrectom...

Full description

Saved in:
Bibliographic Details
Published in:Clinical and translational science 2015-08, Vol.8 (4), p.320-325
Main Authors: Cheng, Yu, Zhou, Jin, Li, Honglun
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
biomarker
eIF3f
Eukaryotic Initiation Factor-3 - analysis
Female
Gastric cancer
Her‐2/neu
Humans
Immunohistochemistry
In Situ Hybridization, Fluorescence
Male
Medical prognosis
Middle Aged
Neoplasm Staging
Original s
Prognosis
Receptor, ErbB-2 - analysis
Stomach Neoplasms - chemistry
Stomach Neoplasms - mortality
Stomach Neoplasms - pathology
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: To detect the expression of eIF3f and human epidermal growth factor receptor 2 (Her‐2)/neu in gastric cancer (GC), correlation with their clinicopathological parameters and the relationship of eIF3f and Her‐2/neu in the occurrence and development of GC. Methods: A total of 195 gastrectomy specimens with stage I to III were examined for eIF3f expression by immunohistochemistry and for Her‐2/neu expression by fluorescence in situ hybridization (FISH) with the median follow‐up period of 38 months. Results: The positive expression rate of eIF3f in GC and adjacent noncancerous tissue were 33.8% and 59.5%, respectively. eIF3f levels were linked to more advanced tumor stages and likelihood of recurrence (all p < 0.05). The Kaplan–Meier survival curves indicated that decreased expression of eIF3f could serve as a prognosis marker for poor outcome of GC patients (p = 0.04). 15.9% of GC specimens were positive for Her‐2/neu, but whose expression was of no correlation with patients’ survival. Patients who were positive for Her‐2/neu also had high eIF3f expression levels (p = 0.0295). Conclusion: Results suggest that eIF3f may play an important role in recurrence, thus representing a promising predictive marker for the prognosis of GC. But Her‐2/neu has no relationship with the prognosis of GC. The clinical significance of eIF3f and Her‐2/neu remains to be further investigated.
ISSN:1752-8054
1752-8062
DOI:10.1111/cts.12263